0001193125-22-071956.txt : 20220310 0001193125-22-071956.hdr.sgml : 20220310 20220310161555 ACCESSION NUMBER: 0001193125-22-071956 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20220310 FILED AS OF DATE: 20220310 DATE AS OF CHANGE: 20220310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Opthea Ltd CENTRAL INDEX KEY: 0001815620 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39621 FILM NUMBER: 22729234 BUSINESS ADDRESS: STREET 1: LEVEL 4 STREET 2: 650 CHAPEL STREET CITY: SOUTH YARRA, VICTORIA STATE: C3 ZIP: 3141 BUSINESS PHONE: 61 3 9826 0399 MAIL ADDRESS: STREET 1: LEVEL 4 STREET 2: 650 CHAPEL STREET CITY: SOUTH YARRA, VICTORIA STATE: C3 ZIP: 3141 6-K 1 d323943d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March 2022

Commission File Number: 001-39621

 

 

OPTHEA LIMITED

(Translation of registrant’s name into English)

 

 

Level 4

650 Chapel Street

South Yarra, Victoria 3141

Australia

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

EXHIBITS

 

Exhibit

   

Description

99.1    Press Release dated March 10, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    OPTHEA LIMITED
Date: March 10, 2022     By:  

/s/ Megan Baldwin

      Megan Baldwin, Ph.D.
      Chief Executive Officer and Managing Director
 EX-99.1 2 d323943dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

ASX, Nasdaq and Media

Release

10 March 2022

Opthea To Present at Oppenheimer’s 32nd Annual Healthcare Conference

Melbourne, Australia; March 10, 2022 – Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at Oppenheimer’s 32nd Annual Healthcare Conference, being held virtually from March 15-17, 2022.

The presentation will be available beginning Tuesday, March 15, at 8:40 am ET (11:40 pm AEDT), and may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/.

About Opthea Limited

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

Authorized for release to ASX by Megan Baldwin, CEO & Managing Director

Company & Media Enquiries:

 

U.S.A. & International:    Australia:
Sam Martin    Rudi Michelson
Argot Partners    Monsoon Communications
Tel: +1 212-600-1902    Tel: +61 (0) 3 9620 3333

opthea@argotpartners.com

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com

GRAPHIC 3 g323943page4.jpg GRAPHIC begin 644 g323943page4.jpg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end